CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
H.C. Wainwright Cell Therapy Virtual Conference
Fireside Chat recording available on Tuesday, February 28, 2023 at 7:00 am ET
Inaugural Mizuho Oncology Therapeutics Summit
Panel: Developing & Commercializing Cell Therapy
Date: Monday, March 13, 2023 at 8:00 am
Location: Cadillac Hotel & Beach Club, Miami, FL
Oppenheimer 33rd Annual Virtual Healthcare Conference
Presentation: Monday, March 13, 2023 at 1:20 pm ET
Barclays Global Healthcare Conference
Fireside Chat: Wednesday, March 15, 2023 at 2:05 pm ET
Location: Loews Miami Beach Hotel, Miami, FL
A live webcast and archived replay of the presentation and fireside chats will be available on the investors section of our website, linked here: https://ir.vorbio.com/events-presentations/
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.60 |
| Daily Change: | -0.14 -8.05 |
| Daily Volume: | 6,102,541 |
| Market Cap: | US$202.690M |
August 27, 2025 July 21, 2025 June 25, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
